CG
ENTA icon

Cutler Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Cutler Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,000
Closed -$1K – 4126
2019
Q3 		$1K Buy
+1,000
New +$74.3K ﹤0.01% 3700
2018
Q4 		– Sell
-3,000
Closed -$2K – 4095
2018
Q3 		$2K Buy
3,000
+2,400
+400% +$240K ﹤0.01% 3478
2018
Q2 		$18K Sell
600
-600
-50% -$59.9K ﹤0.01% 2255
2018
Q1 		$3K Buy
+1,200
New +$92.4K ﹤0.01% 3550
2017
Q4 		– Sell
-300
Closed -$3K – 5129
2017
Q3 		$3K Sell
300
-9,700
-97% -$390K ﹤0.01% 4772
2017
Q2 		$34K Buy
+10,000
New +$320K ﹤0.01% 2867
2017
Q1 		– Sell
-600
Closed -$2K – 6567
2016
Q4 		$2K Sell
600
-4,000
-87% -$115K ﹤0.01% 5579
2016
Q3 		$1K Buy
4,600
+2,400
+109% +$55.7K ﹤0.01% 6085
2016
Q2 		$1K Buy
+2,200
New +$57.6K ﹤0.01% 6034

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cutler Group's ENTA Position: Q4 2020 in Review

Cutler Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 1,820 shares — an estimated $83K sold.

Cutler Group first reported a position in ENTA in Q4 2015 and held it in 13 quarters. The position peaked at $133K in Q1 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Cutler Group reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cutler Group sold 1,820 Enanta Pharmaceuticals shares in Q4 2020, an estimated $83K.
  • Cutler Group first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Enanta Pharmaceuticals position peaked at $133K in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.